Modulation of cytochrome P450 activity: Implications for cancer therapy

Lancet Oncology

Volumn 6, Issue 10, 2005, Pages 780-789

  Scripture, Charity D ^a   Sparreboom, Alex ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DOCETAXEL; DRUG METABOLITE; GLYCOPROTEIN P; IFOSFAMIDE; IRINOTECAN; KETOCONAZOLE; MIDAZOLAM; PACLITAXEL; PHENOBARBITAL; RIFAMPICIN; TAMOXIFEN;

AGE DISTRIBUTION; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; IN VIVO STUDY; LIVER METABOLISM; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SEX DIFFERENCE; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGE FACTORS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; COMORBIDITY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; SEX FACTORS;

EID: 26444516024     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70388-0     Document Type: Review

References (77)

1. SD Baker J Verweij EK Rowinsky et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001 J Natl Cancer Inst 94 2002 1883-1888
2. WE Evans MV Relling Pharmacogenomics: Translating functional genomics into rational therapeutics Science 286 1999 487-491
3. WE Evans HL McLeod Pharmacogenomics: Drug disposition, drug targets, and side effects N Engl J Med 348 2003 538-549
4. LH Patterson GI Murray Tumour cytochrome P450 and drug activation Curr Pharm Des 8 2002 1335-1347
5. MC McFadyen HL McLeod FC Jackson et al. Cytochrome P450 CYP1B1 protein expression: A novel mechanism of anticancer drug resistance Biochem Pharmacol 62 2001 12
6. WA Denny Tumor-activated prodrugs: A new approach to cancer therapy Cancer Invest 22 2004 604-619
7. GU Dachs J Tupper GM Tozer From bench to bedside for gene-directed enzyme prodrug therapy of cancer Anticancer Drugs 16 2005 349-359
8. MM Cotreau LL von Moltke DJ Greenblatt The influence of age and sex on the clearance of cytochrome P450 3A substrates Clin Pharmacokinet 44 2005 33-60
9. V Pichette FA Leblond Drug metabolism in chronic renal failure Curr Drug Metab 4 2003 91-103
10. RH Elbekai HM Korashy AO El-Kadi The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes Curr Drug Metab 5 2004 157-167
11. MT Kinirons MS O'Mahony Drug metabolism and ageing Br J Clin Pharmacol 57 2004 540-544
12. Food and Drug Administration. FDA guidance for industry: In vivo bioequivalence studies based on population and individual bioequivalence approaches 1997 CDER; DHHS Bethesda
13. R Wolbold K Klein O Burk et al Sex is a major determinant of CYP3A4 expression in human liver Hepatology 38 2003 978-988
14. J George K Byth GC Farrell Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver Biochem Pharmacol 50 1995 727-730
15. C Durnas CM Loi BJ Cusack Hepatic drug metabolism and aging Clin Pharmacokinet 19 1990 359-389
16. EA Sotaniemi AJ Arranto O Pelkonen M Pasanen Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions Clin Pharmacol Ther 61 1997 331-339
17. Z Bebia SC Buch JW Wilson et al. Bioequivalence revisited: Influence of age and sex on CYP enzymes Clin Pharmacol Ther 76 2004 618-627
18. CM Hunt WR Westerkam GM Stave JA Wilson Hepatic cytochrome P-4503A (CYP3A) activity in the elderly Mech Ageing Dev 64 1992 189-199
19. KT Kivisto HK Kroemer M Eichelbaum The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions Br J Clin Pharmacol 40 1995 523-530
20. MG Donelli M Zucchetti E Munzone et al. Pharmacokinetics of anticancer agents in patients with impaired liver function Eur J Cancer 34 1998 33-46
21. LP Rivory KA Slaviero SJ Clarke Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response Br J Cancer 87 2002 277-280
22. TC Dowling AE Briglia JC Fink et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease Clin Pharmacol Ther 73 2003 427-434
23. SD Baker RH van Schaik LP Rivory et al. Factors affecting cytochrome P-450 3A activity in cancer patients Clin Cancer Res 10 2004 8341-8350
24. CM Ulrich K Robien HL McLeod Cancer pharmacogenetics: Polymorphisms, pathways and beyond Nat Rev Cancer 3 2003 912-920
25. I Johansson E Lundqvist L Bertilsson et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine Proc Natl Acad Sci USA 90 1993 11825-11829
26. KA Phillips DL Veenstra E Oren et al. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review JAMA 286 2001 2270-2279
27. JH Beijnen JH Schellens Drug interactions in oncology Lancet Oncol 5 2004 489-496
28. H Swaisland RP Smith J Farebrother A Laight The effect of the induction and inhibition of CYP3A4 on the pharmacokinetics of single oral doses of ZD1839 ('Iressa'), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in healthy male volunteers Proc Am Soc Clin Oncol 21 2002 83a
29. VJ Wacher CY Wu LZ Benet Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy Mol Carcinog 13 1995 129-134
30. JH Lin Drug-drug interaction mediated by inhibition and induction of P-glycoprotein Adv Drug Deliv Rev 55 2003 53-81
31. JH Lin M Yamazaki Role of P-glycoprotein in pharmacokinetics: Clinical implications Clin Pharmacokinet 42 2003 59-98
32. K Venkatakrishnan LL Von Moltke DJ Greenblatt Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models J Clin Pharmacol 41 2001 1149-1179
33. AV Boddy SM Yule Metabolism and pharmacokinetics of oxazaphosphorines Clin Pharmacokinet 38 2000 291-304
34. TK Chang GF Weber CL Crespi DJ Waxman Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes Cancer Res 53 1993 5629-5637
35. TK Chang L Yu P Maurel DJ Waxman Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines Cancer Res 57 1997 1946-1954
36. S Ren JS Yang TF Kalhorn JT Slattery Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes Cancer Res 57 1997 4229-4235
37. L Yu DJ Waxman Role of cytochrome P450 in oxazaphosphorine metabolism: deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450 Drug Metab Dispos 24 1996 1254-1262
38. GP Kaijser A Korst JH Beijnen et al. The analysis of ifosfamide and its metabolites Anticancer Res 13 1993 1311-1324
39. LJ Ayash JE Wright O Tretyakov et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response J Clin Oncol 10 1992 995-1000
40. S Maezawa S Ohira M Sakuma et al. Effects of inducer of liver drug-metabolizing enzyme on blood level of active metabolites of cyclophosphamide in rats and in cancer patients Tohoku J Exp Med 134 1981 45-53
41. HJ Xie U Yasar S Lundgren et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation Pharmacogenomics J 3 2003 53-61
42. Human Cytochrome P450 (CYP) Allele Nomenclature Committee CYP2B6 allele nomenclature http://www.imm.ki.se/CYPalleles/cyp2b6.htm (accessed Sept 14, 2005)
43. T Lang K Klein J Fischer et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver Pharmacogenetics 11 2001 399-415
44. T Kerbusch RL Jansen RA Mathot et al. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin Clin Pharmacol Ther 70 2001 132-141
45. B Fisher JP Costantino DL Wickerham et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371-1388
46. CK Osborne Tamoxifen in the treatment of breast cancer N Engl J Med 339 1998 1609-1618
47. E Coezy JL Borgna H Rochefort Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth Cancer Res 42 1982 317-323
48. HK Crewe SW Ellis MS Lennard GT Tucker Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes Biochem Pharmacol 53 1997 171-178
49. Z Desta BA Ward NV Soukhova DA Flockhart Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 2004 1062-1075
50. C Sridar UM Kent LM Notley et al. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6 J Pharmacol Exp Ther 301 2002 945-952
51. VC Jordan MM Collins L Rowsby G Prestwich A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity J Endocrinol 75 1977 305-316
52. V Stearns MD Johnson JM Rae et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 2003 1758-1764
53. V Stearns L Ullmer JF Lopez et al. Hot flushes Lancet 360 2002 1851-1861
54. Y Jin Z Desta V Stearns et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 2005 30-39
55. A Rahman KR Korzekwa J Grogan et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8 Cancer Res 54 1994 5543-5546
56. DS Sonnichsen Q Liu EG Schuetz et al. Variability in human cytochrome P450 paclitaxel metabolism J Pharmacol Exp Ther 275 1995 566-575
57. Human Cytochrome P450 (CYP) Allele Nomenclature Committee CYP2C8 allele nomenclature http://www.imm.ki.se/CYPalleles/cyp2c8.htm (accessed Sept 14, 2005)
58. H Hichiya T Tanaka-Kagawa A Soyama et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R and K383N, found in a Japanese population Drug Metab Dispos 33 2005 630-636
59. N Bahadur JB Leathart E Mutch et al. CYP2C8 polymorphisms in caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes Biochem Pharmacol 64 2002 1579-1589
60. A Soyama Y Saito K Komamura et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift Drug Metab Pharmacokinet 17 2002 374-377
61. D Dai DC Zeldin JA Blaisdell et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid Pharmacogenetics 11 2001 597-607
62. A Sparreboom CD Scripture V Trieu et al. Comparative preclinical and clinical pharmacokinetics of a Cremophor®-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol®) Clin Cancer Res 11 2005 4136-4143
63. M Shou M Martinet KR Korzekwa et al. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver Pharmacogenetics 8 1998 391-401
64. SJ Clarke LP Rivory Clinical pharmacokinetics of docetaxel Clin Pharmacokinet 36 1999 99-114
65. T Shimada H Yamazaki M Mimura et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 caucasians J Pharmacol Exp Ther 270 1994 414-423
66. PB Watkins Noninvasive tests of CYP3A enzymes Pharmacogenetics 4 1994 171-184
67. J Hirth PB Watkins M Strawderman et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance Clin Cancer Res 6 2000 1255-1258
68. BC Goh SC Lee LZ Wang et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies J Clin Oncol 20 2002 3683-3690
69. N Yamamoto T Tamura H Murakami et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol J Clin Oncol 23 2005 1061-1069
70. FK Engels AJ Ten Tije SD Baker et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel Clin Pharmacol Ther 75 2004 448-454
71. M Ciotti N Basu M Brangi IS Owens Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP glucuronosyltransferases encoded at the UGT1 locus Biochem Biophys Res Commun 260 1999 199-202
72. S Marsh H McLeod Pharmacogenetics of irinotecan toxicity Pharmacogenomics 5 2004 835-843
73. A Santos S Zanetta T Cresteil et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans Clin Cancer Res 6 2000 2012-2020
74. DF Kehrer RH Mathijssen J Verweij et al Modulation of irinotecan metabolism by ketoconazole J Clin Oncol 20 2002 3122-3129
75. RH Mathijssen J Verweij P de Bruijn et al. Effects of St John's wort on irinotecan metabolism J Natl Cancer Inst 94 2002 1247-1249
76. RH Mathijssen FA de Jong RH van Schaik et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes J Natl Cancer Inst 96 2004 1585-1592
77. F Innocenti SD Undevia J Ramirez et al. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital Clin Pharmacol Ther 76 2004 490-502